- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00212706
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
October 11, 2012 updated by: Ono Pharmaceutical Co. Ltd
The purpose of this study is to evaluate the efficacy and safety of ONO-8025 (KRP-197) in patients with overactive bladder.
Study Overview
Study Type
Interventional
Enrollment
400
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who are 20 years old or over with overactive bladder
- Total number of urinary incontinence episodes per week is 5 or over
- Mean number of micturition per day is 8 or over
- Mean number of urinary urgency episodes per day is 1 or over
- Other inclusion criteria as specified in the study protocol
Exclusion Criteria:
- Patients with genuine stress incontinence
- Patients suffering from complications such as bladder tumor, bladder stone and urinary tract infection
- Patients who have undergone surgical operation of urinary and/or genital organs within 6 months prior to the study
- Patients suffering from complications for which anticholinergics are contraindicated
- Other exclusion criteria as specified in the study protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Total number of urinary incontinence episodes per week
|
Secondary Outcome Measures
Outcome Measure |
---|
Number of micturition per day, number of urinary urgency episodes per day, volume voided per micturition and QOL
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Project Leader, Development Planning, Ono Pharmaceutical Co. Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2001
Primary Completion (Actual)
November 1, 2002
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 20, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
October 12, 2012
Last Update Submitted That Met QC Criteria
October 11, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONO-8025-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on ONO-8025 (KRP-197)
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharmaceutical Co. LtdKyorin Pharmaceutical Co.,LtdCompletedOveractive BladderJapan
-
Ohio State University Comprehensive Cancer CenterCompletedMalignant NeoplasmUnited States